• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
MRC Laboratory of Molecular Biology

MRC Laboratory of Molecular Biology

One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

  • Home
  • About LMB
  • Research
  • Research Groups
  • Students
  • Recruitment
  • Life at the LMB
  • Achievements
  • News & Events
Home > LMB In The News > Master of Trinity’s Bicycle worth up to $1 billion

Master of Trinity’s Bicycle worth up to $1 billion

Published on 6 December, 2016

Bicycle Therapeutics, the Cambridge biotech company, has done a collaboration deal with AstraZeneca which puts it in line for up to $1 billion. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Sir Gregory Winter (Master of Trinity College, Cambridge) and Prof Christian Heinis. Bicycle is pioneering a new class of drugs based on its bicyclic peptide platform, and will be working with AZ to spot and develop new treatments for respiratory, cardiovascular and metabolic diseases. More…

Primary Sidebar

Search

  • Privacy & Cookies
  • Contact Directory
  • Freedom of Information
  • Site Map
Find Us
©2025 MRC Laboratory of Molecular Biology,
Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK. 01223 267000

The MRC is part of UK Research and Innovation

Contact Us

This site uses cookies. The LMB may use cookies to analyse how you use our website. We use external analysis systems which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our Privacy and Cookies Policy and are integral to our website. You can delete or disable these cookies in your web browser if you wish, but then our site may not work as it is designed. Ok